FountAir From Hong Kong Wins Global Recognition for Breakthrough in Air-to-Water and Cooling Technology
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Hong Kong-based FountAir LTD has been named second runner-up in the Innovative Projects Award (Small Projects category) during the fourth cycle of the Mohammed bin Rashid Al Maktoum Global Water Award. The recognition celebrates the company's revolutionary split-system device, AIR4WATER – 'The Invisible Solution': The First Split VAC-WG, which simultaneously produces clean drinking water and cools air, offering a sustainable solution to address water scarcity and optimise energy consumption.
The award is supervised by the UAE Water Aid Foundation (Suqia UAE), under the Mohammed bin Rashid Al Maktoum Global Initiatives. With total prizes of USD 1 million, it promotes the development of innovative, renewable energy-powered technologies to address global water challenges.
Currently in use across six countries, FountAir's AIR4WATER devices use a split air conditioning-water generation system to condense and purify water from the air, while also cooling indoor spaces. The units are compatible with solar or grid power and produce up to 120 litres of safe, mineral-rich drinking water per day. Independent lab testing confirms the water meets WHO quality standards, with a neutral pH level between 6.92 and 7.
The company's two main models – AIR4WATER 400 Pro and AIR4WATER 120 Home – are now deployed in a factory in China, benefitting over 400 individuals in the pilot phase. Additional units are operational in the Philippines, Indonesia, Kenya, Australia, Lebanon and China, offering affordable water at a marginal cost as low as AED 0.009 per litre when connected only to the electricity grid. FountAir's design combines environmental responsibility and user-centric utility.
'The global water crisis stems from the excessive and irresponsible use of technology for comfort. To accelerate solutions, economic incentives must be aligned with technological innovation. This award is a powerful example, as it brings technology and economy together to drive impact. Our solution empowers users to meet their own water needs, sell the excess and scale up the model sustainably. I thank His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, for bridging the gap between those in need and those with the means and will to support lasting change,' said Jannick Jacques Simeray, founder, inventor and CEO at FountAir.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
37 minutes ago
- Business Wire
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in class, Incyte-discovered, targeted monoclonal antibody in patients with mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms (MPNs). These data – featured today in the Late-Breaking Oral Session (#LB4002) at the European Hematology Association 2025 (EHA2025) Congress in Milan, Italy – focus on the dose escalation portion of the studies in patients with high risk essential thrombocythemia (ET) who are resistant/intolerant to prior cytoreductive therapy. 'These findings, and the further development of INCA033989, offer the potential to significantly transform the treatment of patients with CALR-mutant MPNs," said Pablo J. Cagnoni, M.D., President, Head of Research and Development, Incyte. Share The studies evaluated the safety and efficacy of INCA033989 in patients with ET as measured by hematologic response and reduction in mutCALR variant allele frequency (VAF). Results as of April 4, 2025, showed rapid and durable normalization of platelet counts across all dose levels, with a trend toward improved responses in higher doses (>400 mg), in patients with ET treated with INCA033989. Notably, 86% of patients at doses 400 mg and above achieved a complete or partial hematologic response, with the majority (82%) of patients achieving complete response. Eighty-nine (89) percent of evaluable patients (34/38) showed a reduction in mutCALR VAF from baseline. A partial molecular response (>50% VAF reduction) was observed in 21% of evaluable patients (8/38) after only 3 cycles of treatment. An exploratory study using single-cell DNA (scDNA) sequencing showed that INCA033989 directly targets and reduces cells carrying mutCALR. This reduction was seen in early blood-forming (CD34-positive) cells and cells in the myeloid-erythroid (ME) lineage. At the same time, there was a clear increase in healthy (wild-type CALR) cells, suggesting that the treatment supports the return of normal blood production. Bone marrow biopsies further confirmed these effects showing fewer megakaryocytes with mutCALR protein and a notable increase in megakaryocytes without mutCALR protein. Together, these findings demonstrate the selectivity of INCA033989, allowing for normalization of healthy hematopoiesis and disease modification. 'The late-breaking data presented today highlight the impact of INCA033989, a novel agent that selectively targets mutant CALR, to inhibit and eliminate cancer-causing cells in patients with essential thrombocythemia (ET), while sparing healthy cells and normalizing healthy blood production," said Pablo J. Cagnoni, M.D., President, Head of Research and Development, Incyte. 'These findings, and the further development of INCA033989, offer the potential to significantly transform the treatment of patients with CALR-mutant myeloproliferative neoplasms (MPNs).' The results (N=49) showed that INCA033989 was well tolerated across all dose cohorts (24 to 2,500 mg), with no dose-limiting toxicities observed. Only one (1) patient discontinued treatment, and only one (1) dose reduction due to treatment-emergent adverse events (TEAEs) was observed. No infusion interruptions due to TEAEs were reported, and a maximum tolerated dose was not reached. Forty-two (42) patients across the dose cohorts reported a TEAE. The most common TEAEs were fatigue (26.5%) and upper respiratory tract infection (20.4%), all of which were Grade ≤2. Thirteen (13) patients had Grade >3 TEAEs, with transient asymptomatic lipase increase as the most common (6%). 'mutCALR is the second most common oncogenic driver of MPNs, yet the therapeutic landscape lacks a targeted agent for mutCALR expressing MPNs. Currently, ET treatments aim to prevent vascular complications and improve symptoms but are limited by toxicity and tolerability issues,' said John Mascarenhas, M.D., Professor of Medicine at the Icahn School of Medicine at Mt. Sinai and Director, Center of Excellence for Blood Cancers and Myeloid Disorders, The Tisch Cancer Institute. 'These data support the hypothesis that INCA033989 has the potential not only to normalize platelet counts and provide rapid and durable hematologic responses – but to induce molecular responses, which could potentially change the natural history of the disease.' Additional data from the INCA033989 study in patients with myelofibrosis will be submitted for presentation at a future medical meeting. Discussions with regulatory authorities are planned with the goal to initiate a Phase 3 study by early 2026. More information regarding the EHA2025 Congress and the data from Incyte's hematology/oncology portfolio being featured at the meeting can be found on the EHA website: Incyte Conference Call and Webcast Incyte will host an in-person analyst and investor event on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. ET (12:00 - 1:30 p.m. CEST) to discuss key mutCALR data presented at EHA. The event will be webcasted and can be accessed via the Events and Presentations tab of the Investor section of and it will be available for replay for 30 days. About Myeloproliferative Neoplasms Myeloproliferative neoplasms (MPNs) are a closely related group of blood cancers in which the bone marrow functions abnormally. The bone marrow is where the body's blood cells are made. MPNs are progressive blood cancers that can strike anyone at any age, but they are more common in older adults. Estimates of the prevalence of MPNs vary, but analysis of claims data suggests there may be as many as 200,000 people in the U.S. living with the most prevalent MPNs: myelofibrosis, polycythemia vera or essential thrombocythemia (ET). 1 About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein folding. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), 2 a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. 3,4 Among two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. 2,3 There are approximately 60,000 patients in the U.S. and Europe with mutCALR positive ET. 5 Incyte is at the forefront of developing novel therapies for patients with mutCALR ET or MF that target only malignant cells, sparing normal cells, including INCA033989, a first-in-class, mutCALR-specific therapy. About the INCA033989 Trial Program The clinical trial program for INCA033989 includes two multicenter, open-label Phase 1 studies, INCA33989-101 (NCT05936359) and INCA33989-102 (NCT06034002), enrolling ~225 patients outside of the U.S. and ~140 patients in the U.S., respectively. The studies are evaluating the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). The intent of Part 1A (dose escalation) is to identify the MTD and/or the RDE of INCA033989 among patients with MF and ET. In Part 1A INCA033989 is administered intravenously every two weeks at a protocol defined dose ranging from 24 mg. to 2,500 mg. In Part 1B (dose expansion), INCA033989 is administered at the RDE(s) identified during Part 1A. The primary endpoint of the studies focuses on safety and tolerability as measured by: the number of participants with DLTs up to 28 days, the number of participants with treatment-emergent adverse events (TEAEs) up to 3 years and 60 days, and the number of participants with TEAEs leading to dose modification or discontinuation up to 3 years and 60 days. Secondary endpoints include response rates, mean change of ET total symptom score from baseline, percentage of MF patients achieving spleen volume reduction, MF patient anemia response, mean change in disease-related allele burden and various pharmacokinetics measures up to 3 years and 60 days. For more information on the study, please visit: and About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data for Incyte's anti-mutCALR monoclonal antibody (INCA033989), the potential this monoclonal antibody offers for patients, and expectations regarding ongoing and future clinical trials contain predictions, estimates, and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA, EMA and other regulatory agencies; Incyte's dependence on its relationships with and changes in the plans of its collaboration partners; the efficacy or safety of Incyte's products and the products of Incyte's collaboration partners; the acceptance of Incyte's products and the products of Incyte's collaboration partners in the marketplace; market competition; unexpected variations in the demand for Incyte's products and the products of Incyte's collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for Incyte's products and the products of Incyte's collaboration partners; sales, marketing, manufacturing and distribution requirements, including Incyte's and its collaboration partners' ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional products that become approved; greater than expected expenses, including expenses relating to litigation or strategic activities; variations in foreign currency exchange rates; and other risks detailed in Incyte's reports filed with the Securities and Exchange Commission, including its annual report on form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.
Business Wire
2 hours ago
- Business Wire
Embracing Powertrain Diversity, GWM Continues to Enhance Clean Diesel Capabilities for Off-Roading
BAODING, China--(BUSINESS WIRE)--While new energy vehicles continue to gain momentum worldwide, efficient diesel power remains a compelling choice—especially in challenging off-road environments where torque, range, and reliability are critical. GWM is advancing diesel technology with a focus on refinement, performance, and real-world usability. At the recent GWM Thailand Diesel Day event, the brand demonstrated how modern diesel can deliver a clean, quiet, and highly capable driving experience. Traditional trade-offs—torque versus comfort, power versus fuel economy—are disappearing. With today's drivers demanding both performance and efficiency, GWM's TANK 300 Diesel delivers on all fronts. In Thailand, the TANK 300 Diesel has earned high praise for its impressive torque (480N·m at just 1,500rpm), extended driving range (up to 1,200km), and smooth, quiet ride. As one reviewer noted, 'It drives like a gasoline SUV—quiet and refined—until you need the torque. Then, it just powers through.' This refined balance comes from GWM's 2.4T diesel engine, combined with over 200 NVH (Noise, Vibration, and Harshness) enhancements—bringing idle noise down to just 65dB, comparable to gasoline-powered vehicles. The result: urban comfort with true off-road muscle. GWM's advanced combustion technology—featuring columnar combustion chambers and dual tangential air ducts—cuts fuel consumption to under 7.3L/100km, making long journeys more economical and environmentally responsible. Guided by its 'All Scenarios, All Powertrains, All Users' strategy, GWM's TANK 300 Diesel demonstrates that diesel, when done right, is still a powerful, relevant solution to real-world needs. In markets like Thailand, clean diesel has a promising future. More than just a product launch, GWM's achievement reflects a user-centered innovation that sets a new benchmark. The message to drivers is clear: more power, fewer compromises, and a brand that truly listens.
Axios
2 hours ago
- Axios
Exclusive: Autonomize AI gets $28M for health agents
Autonomize AI, a provider of AI agents to health systems and plans, raised $28 million in Series A funding, CEO Ganesh Padmanabhan tells Axios exclusively. The big picture: It's the latest sign of investor appetite for infrastructure-layer AI in health care — especially platforms that promise scale, compliance, and a clear ROI. Follow the money: Autonomize plans to expand deployment of its "Copilot" AI agents across payers, providers, and life sciences organizations. Valtruis, Cigna Ventures, and Tau Ventures led the round, joined by previous investors Asset Management Ventures, ATX Venture Partners, and Capital Factory. The Series A provides 24-month runway, though the company could raise before then, Padmanabhan says. How it works: Austin-based Autonomize's agentic AI platform stitches together pre-trained agents for tasks like benefits verification, care planning, and chart review. The company uses a human-in-the-loop model and offers explainability and compliance features — two key factors for success in health care. Most of its customers are payors, followed by value-based care providers and syndicated health plans. Between the lines: Autonomize was built specifically for the highly regulated business of health care, per Padmanabhan. "I've met nurses who have a 400-page binder on their desk that they still refer to before making adjudication decisions within health plans," says Padmanabhan. "There's no way an AI agent is going to find that because that data, that knowledge, is not digitized." What they're saying: "The way the technology is configured is, you set up an agent for a particular use case and it's reusable for others," says Valtruis managing director Mike Spadafore. "A lot of these workflows are made up of 15, 20 different steps that you assemble into different workflows," Spadafore adds, noting Autonomize's repeatability was attractive. "A complex workflow, like care management or like prior authorization, is actually multiple sub workflows," Padmanabhan says. A benefit check is one example —where users are looking at patient information across multiple documents. Reality check: The market is flooded with "AI for health care" startups, but most are still struggling to show meaningful, repeatable results.
